www.cryocath.com Toronto Stock Exchange Symbol: CYT
MONTREAL, May 8 /CNW/ - CryoCath Technologies (TSX:CYT), the global
leader in cryotherapy products to treat cardiovascular disease, announced the
presentation of 15 oral abstracts and posters, all pertaining to the use of
CryoCath's technology to treat heart arrhythmias at the 28th Annual Scientific
Sessions of the Heart Rhythm Society, to be held in Denver, Colorado May 9-12,
In addition to these abstracts, CryoCath and cryoablation will be one of
the central themes of a CME-accredited symposium, "Broadening the Range of
Atrial Fibrillation Therapies." Topics will include: Improving the Safety of
Catheter Ablation for Atrial Fibrillation; Focal Catheter Cryoablation
Strategies; Experimental Observations on the Use of Balloon Ablation Catheters
for Atrial Fibrillation and Clinical Experience with CryoBalloon Ablation for
Atrial Fibrillation. As well, two panel discussions, one on the Current Status
of Commercially Available Ablation Catheters and one on Future Directions in
Ablation Technologies in Atrial Fibrillation will be hosted. The symposium
will be co-hosted by key chairs Dr. Wyn Davies of St. Mary's Hospital in
London, England and Dr. Jeremy Ruskin of Massachusetts General Hospital in
Boston, MA. Presenters will include Dr. Vivek Reddy, Dr. Walter Kerwin, Dr.
Douglas Packer and Dr. Karl-Heinz Kuck.
The HRS Educational Leadership Team is also offering two cryo
technology-focused sessions as part of its core curriculum: "Ten Years of
CryoAblation - What Have We Learned?" and "CryoThermal Ablation and other
Energy Sources in Children and Patients with Congenital Heart Disease."
"The fact that the HRS Educational Leadership Team has added these two
sessions as part of the core curriculum is a testament to the increasing use
of cryotherapy in the treatment of heart disease and an invaluable endorsement
in encouraging the use of this technology," said Jan Keltjens, President and
CEO of CryoCath.
CryoCath currently has three electrophysiology products approved for use
in North America and four approved for use in Europe. More than 40,000
patients have been treated with cryoablation using these products at over 400
centers worldwide. The company also has a product, Arctic Front(R), approved
for Investigational Use in the United States. In Europe, more than 750
procedures have already been performed with the technology, a cryo-balloon
specifically designed to treat Atrial Fibrillation.
About Arctic Front
Arctic Front is a minimally invasive cryo-balloon catheter designed
specifically to treat Atrial Fibrillation. This bi-directional, double balloon
catheter enables physicians to rapidly isolate all four pulmonary veins for
the treatment of AF. Approved in Europe, it has treated more than 750 patients
in more than 24 centers.
About Atrial Fibrillation
AF, described as a rapid and chaotic quivering of the top two chambers in
the heart, is the most prevalent arrhythmia, affecting more than 2.3 million
patients in the U.S. with an annual incidence of 170,000 new cases per year.
It is a leading cause of stroke and hospitalizations, and has become the most
common complication of cardiovascular surgery. If left untreated, it can lead
to heart failure and death.
CryoCath - www.cryocath.com - is a medical technology company that leads
the world in cryotherapy products to treat cardiovascular disease. With a
priority focus on providing physicians with a complete solution of catheter
and surgical products to treat cardiac arrhythmias, CryoCath has multiple
products approved in the U.S., across Europe and several ROW countries. The
Company is developing additional products to expand its pipeline of products
to treat cardiac arrhythmias.
This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of
regulatory trials and their outcome. For information identifying
legislative or regulatory, economic, climatic, currency, technological,
competitive and other important factors that could cause actual results
to differ materially from those anticipated in the forward-looking
statements, see CryoCath's annual report available at www.sedar.com
under the heading Risks and Uncertainties in the Management's Discussion
and Analysis section.
For further information:
For further information: visit our website at www.cryocath.com, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail: firstname.lastname@example.org